Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org
18.07.2025 16:30 — 👍 1 🔁 0 💬 0 📌 0
Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss!
Register now: surveys.mayoclinic.org/jfe/form/SV_...
09.07.2025 17:35 — 👍 1 🔁 1 💬 1 📌 0
TALENT — The PCCTC
Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent
16.06.2025 23:38 — 👍 0 🔁 0 💬 0 📌 0
#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”
03.06.2025 21:20 — 👍 2 🔁 0 💬 0 📌 0
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
03.06.2025 13:30 — 👍 3 🔁 1 💬 0 📌 1
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
02.06.2025 16:11 — 👍 0 🔁 0 💬 0 📌 0
Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343
Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343
01.06.2025 13:04 — 👍 2 🔁 0 💬 0 📌 0
Mark Your Calendar! 📆 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss!
Register now: surveys.mayoclinic.org/jfe/form/SV_...
30.05.2025 15:38 — 👍 1 🔁 1 💬 0 📌 0
The Prostate Cancer Clinical Trials Consortium at ASCO 2025: Abstracts Listing
#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!
28.05.2025 18:38 — 👍 2 🔁 0 💬 0 📌 0
The PCCTC at ASCO25: Oral Abstract Sessions
3 June | Hall D1 | Live Stream
#5002: Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry..
Presenter: Michael Ong, MD, BSc, FRCPC (The Ottawa Hospital Cancer Centre)
10:33 AM – 10:45 AM CDT
#5007: A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
Presenter: Rana R. McKay, MD, FASCO (University of California San Diego)
11:57 AM – 12:09 PM CDT
The PCCTC at ASCO25: Rapid Oral Abstract Sessions
1 June | Hall D2 | Live Stream
#5014: Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.
Presenter: Eric Huttenlocher Bent, MD, PhD (MSK)
4:42 PM – 4:48 PM CDT
#5015: DB‑1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
Presenter: Andrew Ohyama Parsonson, FRACP, MBBS (Macquarie University)
5:00 PM – 5:06 PM CDT
#5017: Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Capucine Baldini, MD, PhD (Institut Gustave Roussy)
5:12 PM – 5:18 PM CDT
The PCCTC at ASCO25: Poster Sessions
Gupta S, et al. Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study. Abstract # 5043, Poster Bd # 242.
Von Amsberg G, et al. Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC). Abstract # 5059, Poster Bd #258.
Marulanda Corzo V, et al. PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes. Abstract # 5070, Poster Bd # 269.
Bryce A, et al. Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Abstract # 5071, Poster Bd # 270.
Attwell M, et al. A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC). Abstract # TPS5123, Poster Bd # 315b.
Wise D, et al. Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC). Abstract # 5067, Poster Bd #266.
Johnson G, et al. SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer. Abstract # TPS5125, Poster Bd # 316b.
The PCCTC at ASCO25: Publication Only Abstracts
Sokolova A, et al. Barriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC). Abstract # e17073.
George D, et al. Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study. Abstract # e17076.
Schweizer M, et al. Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC). Abstract # e17032.
Alonso Gordoa T, et al. Mevrometostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. Abstract # e17029.
We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!
22.05.2025 21:05 — 👍 1 🔁 0 💬 0 📌 0
At MSK, there are exciting new therapies that are proving effective at treating metastatic prostate cancer.
In this 📹, Dr. Michael Morris, a genitourinary medical oncologist and the Prostate Cancer Section Head at MSK, speaks about one in particular.
Plus, read more here: bit.ly/4mfOKhg
20.05.2025 15:25 — 👍 3 🔁 1 💬 0 📌 0
We’re headed to Lagos for the IRONMAN Conference from September 4–6, with a special pre-conference session on September 3. This isn’t just an event—it’s a major milestone in global health and cancer research you won’t want to miss!
Register now: surveys.mayoclinic.org/jfe/form/SV_...
15.05.2025 18:32 — 👍 1 🔁 1 💬 0 📌 0
Cover page of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer
Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...
02.05.2025 18:05 — 👍 0 🔁 0 💬 0 📌 0
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons: In 2020, BLOODPAC recommended 11 pre-analytical minimal technical data elements for collection and submission of liquid biopsy data to public databases. This article expands on that work by recommending 22 clinical context and 10 patient context data elements. These elements, essential for liquid biopsy data submitted to repositories like the BLOODPAC Data Commons, cover tumor characteristics, disease progression, and patient demographics, supporting biomarker validation, research, and clinical trials.
Just Published: PCCTC leadership and colleagues release recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons (Clin Transl Sci): pmc.ncbi.nlm.nih.gov/articles/PMC...
01.05.2025 13:02 — 👍 0 🔁 0 💬 0 📌 0
Stats & DS @ UCSB '26, data science intern at the PCCTC.
Currently into: biostatistics, data visualization, summer reading, fencing. Warning for the occasional cat picture.
Urology Resident & Doctoral Student in Clinical Epidemiology at the University of Toronto | Alum of McGill Medicine & Harvard Chan School of Public Health | he/him
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
🌐 JAMAOncology.com
Director of Genitourinary Program in Radiation Oncology at @mskcancercenter.bsky.social
Runs to Fundraise for Prostate Cancer Awareness and Research
Accelerating the development and validation of #liquidbiopsy assays to improve the outcomes of patients with #cancer. Not-for-profit.
Pathologist & urologist focused on #gupath. Also working in #gynpath, #gipath, #dermpath & #cytopath.
Genitourinary medical oncologist
📚 Home of #EuropeanRadiology and #EuropeanRadiologyExperimental
🔵 https://www.european-radiology.org/
🟢 https://www.er-x.org/
🤖 ESR #AI blog ➡️ http://ai.myesr.org
Social Media Editor: @brenkelly.bsky.social
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Chief Clinical Officer, City of Hope Chicago
Research, news, and commentary from Nature, the international science journal. For daily science news, get Nature Briefing: https://go.nature.com/get-Nature-Briefing
Director of the Lurie Cancer Center @luriecancer.bsky.social of Northwestern University. Medical oncologist and cancer researcher. Views & opinions here are my own.
Assistant Professor (incoming) CPDR/USUHS • PhD in Bioinformatics • Data Scientist • Cancer Genomics | MD, USA 🧬💻🔬 🇳🇵 🇨🇦 🇺🇸
An @nihr.bsky.social partnership between @cuh.nhs.uk and the University of Cambridge @cam.ac.uk We research different diseases to find new treatments & medicines. Based at CUH & Cambridge Biomedical Research Centre https://cambridgebrc.nihr.ac.uk
President, American Cancer Society Cancer Action Network (ACS CAN). Cancer Fighting Advocate. Mom to gang of 4.
National Institute for Health and Care Research - we fund, enable and deliver world-leading health and social care research that improves people's health and wellbeing, and promotes economic growth.
Impact, Innovation, Investment, Inclusion
Kidney Advocate, 50 year PKD Patient, Streamyard Broadcaster, Prolific Poster, Please no Crypto, Investing and Sexual DMs. Views are my own
ASTRO: The American Society for Radiation Oncology.
Targeting Cancer Care.
ASTRO website: http://ASTRO.org
Patient education info at http://RTanswers.org
#radonc #medphys #radbio #DEIinRO
The online destination for oncology professionals
Free access for registered Healthcare Professionals and home of "The Oncology Podcast"
Join us today for the latest oncology news, commentary, educational resources and podcasts
oncologynetwork.com.au
